Powerful Combination Harnesses High-Throughput Performance of Clarus 600 GC/MS with Fast and Easy-to-Understand Deconvolution Software
BOSTON, MA -- November 13, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced a new partnership with Ion Signature Technology, Inc. (IST). Users of the new PerkinElmer Clarus® 600 GC/MS now have the option to incorporate Ion Signature Quantitative Deconvolution Software™ customized for the Clarus family during data processing for fast and accurate data review and evaluation.
“The Clarus GC/MS and Ion Signature Quantitative Deconvolution software work in concert to enable users to rapidly quantify target compounds and identify unknowns in complex GC/MS samples,” said Jonathan Rennert, vice president and general manager, Analytical Sciences, for PerkinElmer’s Life and Analytical Sciences division. “This partnership supports our overall goal to provide solutions that help advance the pace and precision of scientists’ research and testing.”
The recently launched family of Clarus 600 GC/MS systems delivers high performance and increased sample throughput. For many laboratories, adding the Ion Signature option further enhances the Clarus system’s ability to deliver faster results on unknowns. “It provides a tool for laboratories to more efficiently identify target compounds present in even difficult and complex samples,” Rennert said. “By combining this powerful deconvolution capability with the fastest analytical cycle time capabilities delivered by the Clarus 600 GC/MS, customers can significantly increase their analysis and identification of organic compounds. Consequently, it is anticipated that scientists will reap an even greater return on their GC/MS investment.”
The Ion Signature FileConvert software package, designed specifically for use with the PerkinElmer Clarus GC/MS series, is the most powerful deconvolution tool in the marketplace. It addresses the needs of the full spectrum of GC/MS users, including environmental contract, forensics, food and beverage, flavor and fragrance, petrochemical and chemical quality-control (QC) laboratories. In these market segments, users face unique co-eluting challenges when multiple components or contaminants overlap at the results stage, which make the clear interpretation of data difficult.
To avoid such challenges, the PerkinElmer TurboMass™ GC/MS software first performs the data acquisition. The IST deconvolution software then comes into play to simplify the complex compounds before the data processing stage to ensure accurate identification.
“We leverage proprietary, advanced algorithms that make it easy to analyze even the most difficult and complex samples,” said John Moore, president and CEO of Rhode Island-based Ion Signature Technology, the market leader in deconvolution technology. “Our technology enables users to untangle co-eluting peaks and examine each uniquely, providing a one-of-a-kind ‘fingerprint’ of the unknown. For complex samples with many compounds, conventional analysis would take significantly longer and the end result may yield questionable results.”
For more information about the Clarus 600 GC/MS and the Ion Signature Quantitative Deconvolution Software, visit www.perkinelmer.com/Clarus600GCMS.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.